AstraZeneca announced $3.5 billion of capital investment in the United States to expand the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating over 1,000 new and high-skilled jobs contributing to the growth of the US economy.
AstraZeneca’s expanding footprint in the US includes:
— A state-of-the-art R&D center at Kendall Square in Cambridge, Massachusetts
— A next-generation manufacturing facility for biologics in Maryland
— Cell therapy manufacturing capacity on the West and East Coasts
— Specialty manufacturing in Texas
These US investments are the first of a series of steps to help deliver AstraZeneca’s ambition to achieve $80 billion in Total Revenue by 2030 as set out in May this year. A key element of our strategy is accelerating the company’s development in the United States. The US is AstraZeneca’s largest market, generating about 44% of its Total Revenue.
AstraZeneca has about 17,800 employees working across 17 R&D, manufacturing, and commercial sites spanning 12 states.
KEY QUOTE:
“Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”
– Pascal Soriot, Chief Executive Officer, AstraZeneca
